Investors bought shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on weakness during trading on Wednesday. $63.24 million flowed into the stock on the tick-up and $41.86 million flowed out of the stock on the tick-down, for a money net flow of $21.38 million into the stock. Of all companies tracked, Regeneron Pharmaceuticals had the 19th highest net in-flow for the day. Regeneron Pharmaceuticals traded down ($4.03) for the day and closed at $468.54
A number of research analysts recently commented on the stock. Leerink Swann reiterated an “outperform” rating and set a $573.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 22nd. Raymond James Financial, Inc. reiterated an “outperform” rating and set a $547.00 price objective (up previously from $475.00) on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 22nd. BMO Capital Markets reiterated a “market perform” rating and set a $484.00 price objective (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. Bank of America Corporation reiterated a “buy” rating and set a $593.00 price objective (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. Finally, BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $495.59.
The stock’s 50 day moving average price is $490.71 and its 200 day moving average price is $430.04. The company has a market capitalization of $49.20 billion, a P/E ratio of 46.55 and a beta of 1.66.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter in the prior year, the company posted $2.82 earnings per share. The firm’s revenue was up 21.2% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.85 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 9,295 shares of the stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $458.14, for a total value of $4,258,411.30. Following the completion of the sale, the chairman now owns 414,156 shares in the company, valued at $189,741,429.84. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Robert J. Terifay sold 21,147 shares of the stock in a transaction on Friday, June 16th. The shares were sold at an average price of $468.19, for a total transaction of $9,900,813.93. Following the completion of the sale, the executive vice president now owns 72,043 shares of the company’s stock, valued at approximately $33,729,812.17. The disclosure for this sale can be found here. Insiders have sold 56,922 shares of company stock valued at $27,383,105 in the last 90 days. 10.40% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. Korea Investment CORP boosted its stake in shares of Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares in the last quarter. Fieldpoint Private Securities LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $130,000. Sterling Investment Advisors Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 11.2% in the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 28 shares in the last quarter. FNY Managed Accounts LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $140,000. Finally, FNY Partners Fund LP boosted its stake in shares of Regeneron Pharmaceuticals by 200.0% in the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 67.16% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Investors Buy Shares of Regeneron Pharmaceuticals, Inc. (REGN) on Weakness” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://sportsperspectives.com/2017/08/18/investors-buy-shares-of-regeneron-pharmaceuticals-inc-regn-on-weakness.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.